Experience

Davis Polk advised the joint book-running managers on the Rule 144A/Regulation S offering by SEB of $1 billion aggregate principal amount of 0.550% notes due 2023, $600 million…

Davis Polk advised NatWest Group plc (formerly The Royal Bank of Scotland Group plc), a public limited company incorporated under the laws of Scotland, in connection with its SEC-registered…

Davis Polk advised Delek Drilling Limited Partnership, as sponsor, on the Rule 144A offering by its special-purpose vehicle Leviathan Bond Ltd.’s $2.25 billion principal amount of four…

Davis Polk is advising Dufry AG in connection with its proposed acquisition of all the equity interests in Hudson Ltd. it does not already own for $7.70 in cash per Hudson Class A share…

Davis Polk advised Cellnex Telecom, S.A. as to U.S. law in connection with its offering of 101,382,140 new ordinary shares pursuant to a public rights offering in Spain and private…

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…

Davis Polk advised the underwriters on the registered offering of $700 million aggregate principal amount of 1.100% notes due 2030 and $300 million aggregate principal amount of 2.000%…

Davis Polk advised Hangzhou Tigermed Consulting Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in…

Davis Polk is advising UBS AG London Branch as sponsor in connection with the unification of Unilever’s dual-headed group legal structure under a single parent company, Unilever PLC, to be…

Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of 5,500,000 American Depositary Shares of BioNTech SE. In addition,…